Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

Figure 4

Swim plot showing the increase in progression-free survival (PFS) compared with the patients’ previous therapies. The bars represent the progression-free survivals (PFSs) of the DAC (a) and DAC combined with chemo (b) or CIK (c) versus the PFSs following the patients’ previous therapies. Four patients had died by the first assessment (due to disease progression) and were therefore not evaluated. ∗ The patients’ progression-free survivals (PFSs) were significantly prolonged compared with those of previous therapies; 𝑃 value <0.05 was considered significant. CIK: cytokine induced killer cells. # Patients with disease progression. ▲ Patients who died.